[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590910":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":33,"locations":39,"responsibleParty":84,"collaborators":28,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":28,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":28,"enrollmentInfo":95,"targetDuration":28,"studyType":98,"phases":99,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":42,"whyStopped":28,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Jacobio Pharmaceuticals Co., Ltd.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation (Phase 1a)","EXPERIMENTAL","Evaluate overall Safety, tolerability, and determine MTD of JAB-23E73 monotherapy.",[13],"Drug: JAB-23E73",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion \u002F Optimization Phase (Phase 1b)","Determine RP2D of JAB-23E73 in patients with KRAS-alternated NSCLC or other selected tumors",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Indication Expansion (Phase 2a)","Evaluate the preliminary antitumor activity of JAB-23E73 monotherapy at the RP2D in patients with advanced or metastatic CRC, PDAC, and other solid tumors.",[13],[23,29,31],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","JAB-23E73","Oral administration",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":30,"otherNames":28},[15],{"type":24,"name":25,"description":26,"armGroupLabels":32,"otherNames":28},[19],[34],{"name":35,"role":36,"phone":37,"phoneExt":28,"email":38},"Jacobio Pharmaceuticals","CONTACT","(781) 918-6670","clinicaltrials@jacobiopharma.com",[40,54,64,74],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":28},"Mayo Clinic","RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-92.4699,44.02163,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":57,"zip":58,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":63,"contacts":28},"Washington University","St Louis","Missouri","63110",{"type":49,"coordinates":60},[61,62],-90.19789,38.62727,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":67,"zip":68,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":73,"contacts":28},"Cleveland Clinic Foundation","Cleveland","Ohio","44195",{"type":49,"coordinates":70},[71,72],-81.69541,41.4995,{"lat":72,"lon":71},{"facility":75,"status":42,"city":76,"state":77,"zip":78,"country":46,"countryCode":47,"cosmosGeoPoint":79,"geoPoint":83,"contacts":28},"Huntsman Cancer Institute","Salt Lake City","Utah","84112",{"type":49,"coordinates":80},[81,82],-111.89105,40.76078,{"lat":82,"lon":81},{"type":85,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100590910","phase-1-jab-23e73-in-adult-participants-with-advanced-solid-tumors-with-kras-alteration-100590910",false,"NCT06973564","JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration","A Phase 1\u002F2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration","Inclusion Criteria:\n\n* Written informed consent.\n* Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).\n* Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.\n* Patients must have KRAS alterations.\n* Participants are required to provide an archived tumor sample.\n* Patients with a life expectancy ≥3 months.\n* ECOG performance status score of 0 or 1.\n* Patients must have at least one measurable lesion as defined by RECIST v1.1.\n\nExclusion Criteria:\n\n* Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.\n* Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan\u002Fmulti-KRAS inhibitors.\n* Known serious allergy to JAB-23E73 or excipient.\n* Patients with primary central nervous system tumors.\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.\n* QT interval\\>470 msec.\n* LVEF ≤50% assessed by ECHO or MUGA.","ALL","18 Years",{"count":96,"type":97},294,"ESTIMATED","INTERVENTIONAL",[100,101],"PHASE1","PHASE2","This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors",[104],"Advanced Solid Tumors",[106,107,108,109,110,111,112,113,114,25],"KRAS","KRAS mutation","KRAS G12C, KRAS G12D, KRAS G12V, KRAS G12S, KRAS G12A, KRAS G12D","Pan-KRAS","Targeted Therapy","NSCLC","Pancreas cancer","Colorectal cancer","KRAS-mutant tumor","2026-01-14",{"date":117,"type":118},"2026-01-16","ACTUAL",{"date":120,"type":118},"2025-05-29",{"date":122,"type":97},"2028-02",{"name":5,"class":6},4]